Evidence map›Paper›PMID 28818094›Full record

ArticleRadiation oncology (London, England)2017

Radiotoxicity in robotic radiosurgery: proposing a new quality index for optimizing the treatment planning of brain metastases.

Alexandra Hellerbach, Klaus Luyken, Mauritius Hoevels, Andreas Gierich, Daniel Rueß, Wolfgang W Baus, Martin Kocher, Maximilian I Ruge, Harald Treuer

Abstract read
In one paragraph

Article in Radiation oncology (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Impact of prescription isodose level and collimator selection on dose homogeneity and plan quality in robotic radiosurgery.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022
    Article
  4. Tumor-dose-rate variations during robotic radiosurgery of oligo and multiple brain metastases.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexandra HellerbachDepartment of Stereotaxy and Functional Neurosurgery, University Hospital Cologne, Cologne, Germany. alexandra.hellerbach@uk-koeln.de.ORCID http://orcid.org/0000-0001-5821-6267
Klaus LuykenDepartment of Stereotaxy and Functional Neurosurgery, University Hospital Cologne, Cologne, Germany.
Mauritius HoevelsDepartment of Stereotaxy and Functional Neurosurgery, University Hospital Cologne, Cologne, Germany.
Andreas GierichDepartment of Stereotaxy and Functional Neurosurgery, University Hospital Cologne, Cologne, Germany.
Daniel RueßDepartment of Stereotaxy and Functional Neurosurgery, University Hospital Cologne, Cologne, Germany.
Wolfgang W BausDepartment of Radiotherapy, University Hospital Cologne, Cologne, Germany.
Martin KocherDepartment of Radiotherapy, University Hospital Cologne, Cologne, Germany.
Maximilian I RugeDepartment of Stereotaxy and Functional Neurosurgery, University Hospital Cologne, Cologne, Germany.
Harald TreuerDepartment of Stereotaxy and Functional Neurosurgery, University Hospital Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs irradiated brain volume at 12 Gy (V12) is a predictor for radionecrosis, the purpose of the study was to develop a model for Cyberknife (CK) plans that is able to predict the lowest achievable V12 at a given tumor size and prescription dose (PD), and to suggest a new quality index regarding V12 for optimizing the treatment planning of brain metastases.

methodIn our model V12 was approximated as a spherical shell around the tumor volume. The radial distance between tumor surface and the 12 Gy isodose line was calculated using an approximation of the mean dose gradient in that area. Assuming a radially symmetrical irradiation from the upper half space, the dose distribution is given by the superposition of single fields. The dose profiles of a single field were derived by the measured off-center ratios (OCR) of the CK system. Using the calculated gradients of the sum dose profiles, minimal-V12 was estimated for different tumor sizes. The model calculation was tested using a phantom dataset and retrospectively applied on clinical cases.

resultsOur model allows the prediction of a best-case scenario for V12 at a given tumor size and PD which was confirmed by the results of the isocentric phantom plans. The results of the non-isocentric phantom plans showed that an optimization of coverage caused an increase in V12. This was in accordance with the results of the retrospective analysis. V12 s of the clinical cases were on average twice that of the predicted model calculation. A good agreement was achieved for plans with an optimal conformity index (nCI). Re-planning of cases with high V12 showed that lower values could be reached by selecting smaller collimators and by allowing a larger number of total MU and more MU per beam.

conclusionsV12 is a main parameter for assessing plan quality in terms of radiotoxicity. The index f12 defined as the ratio of V12 from the actual plan with the evaluated V12 from our model describes the conformity of an optimally possible V12 and thus can be used as a new quality index for optimizing treatment plans.

Indexed as

Brain NeoplasmsHumansModels, TheoreticalNeoplasm MetastasisPhantoms, ImagingRadiation InjuriesRadiometryRadiosurgeryRadiotherapy Planning, Computer-AssistedRobotic Surgical ProceduresBrain metastasesDose fall-off predictionDosimetryRadiotoxicityRobotic radiosurgeryStereotactic radiosurgery

Identifiers

PMID28818094
PMCPMC5561581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.